Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of flibanserin drops in China. Welcome to wholesale bulk high quality flibanserin drops for sale here from our factory. Good service and reasonable price are available.
Flibanserin Drops is a multi-target neurotransmitter modulator that can be fine tuned by titration at a dose of 5-20 mg/time. Mucosal absorption may be shortened to 30-60 minutes, making it more acceptable for children, the elderly, and patients with swallowing disorders. Flibanserin has extremely low solubility in water (<0.1 mg/mL), so it needs to form salt forms (such as hydrochloride or phosphate), use cyclodextrin inclusion technology, and then add cosolvents (such as propylene glycol, polyethylene glycol 400). At the same time, its bitterness needs to be masked, and ion exchange resin or microencapsulation technology can be used. For dose accuracy, a high-precision dropper is required to ensure that the volume error per drop is less than 5%.
Our products
Additional information of chemical compound:
|
|
|
Flibanserin COA
Mid seam dorsal nucleus - the "upstream switch" for initiating action
Hyposexual desire disorder (HSDD) is a common female sexual dysfunction characterized by sustained or recurrent decreased sexual interest or arousal, significant distress during sexual activity, and not caused by other mental illnesses, medication side effects, or interpersonal relationship problems. Pre menopausal women are at high risk for HSDD, which seriously affects their quality of life and partner relationships. As the world's first approved drug for treating HSDD in premenopausal women, the core mechanism of action of Flibanserin Drops lies in its regulation of the Dorsal Raphe Nucleus (DRN) in the brain. The dorsal raphe nucleus, as the main source of 5-hydroxytryptamine (5-HT) in the brain, contains various neurons such as dopamine (DA) and gamma aminobutyric acid (GABA), and plays an important role in regulating functions such as emotion, cognition, and reward. Flubanserin improves HSDD symptoms by regulating the neurotransmitter system of the dorsal raphe nucleus, forming a "triple regulation" pattern, restoring the normal function of the sexual desire regulatory network.
The structure and function of the dorsal nucleus of the midline
Anatomical location and neuronal composition of the dorsal raphe nucleus
The dorsal raphe nucleus is located in a narrow area near the midline of the brainstem and is the main site of the brain containing serotonin neurons. The raphe nucleus group includes multiple subnuclei, among which the raphe dorsal nucleus has attracted much attention due to its unique anatomical location and functional characteristics. The dorsal raphe nucleus not only contains a large number of 5-hydroxytryptamine neurons (about one-third of the total types of neurons in the nucleus), but also dopaminergic, GABAergic, glutamatergic, and peptide neurons. The diversity of this type of neuron allows the dorsal raphe nucleus to participate in the regulation of various brain functions.
Projection fibers and functional connections of the dorsal raphe nucleus
The ascending projection fibers of the dorsal raphe nucleus are widely distributed in multiple regions of the brain, including the central gray matter of the midbrain, hypothalamus, the parietal nucleus of the dorsal thalamus, cerebellum, amygdala cluster, hippocampal structure, septal nucleus, caudate putamen nucleus, and frontal cortex. These projection fibers enable the dorsal raphe nucleus to participate in the regulation of various functions such as emotions, cognition, rewards, and memory. For example, the projection from the dorsal raphe nucleus to the prefrontal cortex plays an important role in cognitive control and emotional regulation; The projection to the amygdala is involved in the regulation of fear and anxiety emotions; The projection to the nucleus accumbens is closely related to reward and motivational behavior.
The role of the dorsal raphe nucleus in regulating emotions and cognition
The 5-hydroxytryptamine neurons in the dorsal raphe nucleus play a crucial role in emotion regulation. 5-hydroxytryptamine, as an important neuromodulator, is involved in regulating various emotional states such as depression, anxiety, and aggressive behavior. The serotonergic neurons in the dorsal raphe nucleus release serotonin into multiple brain regions through their extensive projection fibers, thereby regulating the activity status of these brain regions. For example, the projection from the dorsal raphe nucleus to the prefrontal cortex can suppress excessive excitation of prefrontal cortex neurons and maintain emotional stability; Projection to the amygdala can suppress excessive activation of the amygdala and reduce the production of anxiety and fear emotions.
In terms of cognitive regulation, dopaminergic neurons in the dorsal raphe nucleus play an important role. Recent studies have shown that dopaminergic neurons in the dorsal raphe nucleus are an independent midbrain dopamine subsystem that exists parallel to dopaminergic neurons in the ventral tegmental area (VTA). Dopaminergic neurons in the dorsal raphe nucleus are involved in the regulation of significant encoding, memory expression, and arousal functions. For example, dopaminergic neurons in the dorsal raphe nucleus can encode the significance of reward and punishment related stimuli, and are regulated by animal physiological states and reward sizes; In terms of memory expression, dopaminergic neurons in the dorsal raphe nucleus project to areas such as the amygdala and striatum, participating in memory consolidation and retrieval; In terms of arousal regulation, dopaminergic neurons in the dorsal raphe nucleus maintain the body's arousal state by promoting activity in arousal related brain regions.
The "triple regulation" mode of fluobanserin in the dorsal raphe nucleus
The mechanism of action of fluoxetine in the dorsal raphe nucleus can be summarized as a "triple regulation" mode, which synergistically regulates the serotonin, dopamine, and noradrenaline systems. This mode is realized through the following ways:
Flubanserin regulates the function of the serotonin system in the dorsal raphe nucleus by activating the serotonin 1A receptor and antagonizing the serotonin 2A receptor. This regulatory effect can:
Inhibit excessive excitation of 5-hydroxytryptamine neurons in the dorsal raphe nucleus and maintain emotional stability;
Relieve the inhibitory effect of serotonin on dopaminergic and noradrenergic neurons, and enhance the release of these neurotransmitters;
Regulating glutamate transmission and improving cognitive control function;
By desensitizing its own receptors, it moderately increases the level of serotonin in synaptic cleft to prevent excessive emotional suppression.
Second Regulation: Enhancement of Dopamine System
Flubanserin indirectly enhances the dopamine system function of the dorsal raphe nucleus by regulating the serotonin system. This regulatory effect can:
Enhance dopamine release from the dorsal raphe nucleus to the nucleus accumbens and prefrontal cortex, improve reward motivation and cognitive flexibility;
Regulating dopamine receptor function to prevent side effects caused by excessive activation of the dopamine system;
Activation of dopamine D4 receptors promotes the generation and maintenance of sexual interest.
adverse reaction
Flibanserin Drops is a medication used to treat acquired, pervasive low libido disorder (HSDD) in premenopausal women. Its mechanism of action involves regulating neurotransmitters such as dopamine, norepinephrine, and serotonin in the brain. Although the drug provides treatment options for specific patient populations, its adverse reactions cannot be ignored.
Common adverse reactions
Dizziness: It is one of the most common adverse reactions in the treatment of fluoxetine, with a high incidence rate. In clinical trials, the incidence of dizziness was significantly higher in patients treated with fluoxetine than in the placebo group. Dizziness may affect patients' daily activities such as walking, driving, etc., increasing the risk of falls and injuries.
Sleepiness: Flibanserin has a central nervous system inhibitory effect, which may cause patients to feel drowsy or fatigued. This drowsiness may be particularly evident in the early stages of treatment, affecting the patient's work efficiency and quality of life.
Insomnia: Although Flibanserin is usually recommended to be taken before bedtime to reduce adverse reactions such as drowsiness and dizziness, some patients may still experience insomnia symptoms. Insomnia may manifest as difficulty falling asleep, sleep maintenance disorders, or early awakening, further affecting the patient's mental state and physical health.
Fatigue: Fatigue is another common adverse reaction of Flibanserin treatment, which may manifest as general weakness, lack of energy, etc. This feeling of fatigue may persist, affecting the patient's daily activities and social functioning.
Nausea: Nausea is one of the common digestive system adverse reactions in the treatment of fluconazole. Nausea may occur alone or accompanied by symptoms such as vomiting and loss of appetite, affecting the patient's nutritional intake and physical health.
Dry mouth: Dry mouth is another common adverse reaction of Flibanserin Drops treatment, which may manifest as dry oral mucosa, thirst, etc. Dry mouth may increase the risk of dental caries and oral infections in patients, and corresponding oral care measures need to be taken.
Constipation: Some patients may experience constipation symptoms during treatment with Flibanserin. Constipation may manifest as reduced frequency of bowel movements, dry and hard stools, etc., increasing the risk of patients developing anal and rectal diseases such as hemorrhoids and anal fissures.
Dry mouth, as one of the common adverse reactions, may also cause problems such as bad breath due to a decrease in oral self-cleaning ability, in addition to the above-mentioned effects. It needs to be alleviated by increasing drinking water and using artificial saliva.
Serious adverse reactions
Hypotension and fainting
Hypotension: Flibanserin may cause hypotension, especially when patients suddenly stand up from a lying or sitting position. Hypotension may lead to symptoms such as dizziness, darkening of the eyes, fatigue, and in severe cases, it may even cause fainting.
Fainting: Fainting is one of the serious adverse reactions of Flibanserin treatment, which may be caused by various factors such as hypotension and central nervous system inhibition. Fainting may cause patients to fall and get injured, and even endanger their lives. Therefore, patients should avoid sudden changes in position, such as quickly standing up from a lying or sitting position, during treatment with fluoxetine.
Central nervous system depression
Symptom manifestation: Flibanserin has a central nervous system inhibitory effect, which may lead to central nervous system depression symptoms in patients, such as slow breathing, difficulty breathing, blurred consciousness, and difficulty maintaining wakefulness.
Risk factors: The risk of central nervous system depression may increase due to the patient's concurrent use of other central nervous system inhibitors (such as alcohol, sedatives, hypnotics, etc.). Therefore, patients should avoid drinking alcohol and using other central nervous system inhibitors during treatment with fluoxetine.
Allergic reactions
Symptoms: Flibanserin may cause allergic reactions, including skin itching, rash, urticaria, angioedema, etc. Severe allergic reactions may manifest as difficulty breathing, laryngeal edema, anaphylactic shock, etc., endangering the patient's life.
Treatment measures: If patients experience allergic reactions during treatment with Flibanserin, they should immediately stop taking the medication and seek medical attention. Doctors will take corresponding treatment measures based on the severity of the patient's symptoms, such as using antihistamines, glucocorticoids, etc. to alleviate allergy symptoms, and providing emergency treatment if necessary.
The story of Flubanserin Droplets does not begin with the formulation itself, but rather with a failed antidepressant development project by the German pharmaceutical company Boehringer Ingelheim in the 1990s. At that time, the global psychiatric drug market was focusing on the development of serotonin (5-HT) receptor modulators, and Boehringer Ingelheim's research and development team turned their attention to a new type of piperazine derivative - a compound codenamed BIMT-17, with the chemical name 3- (2- (4- (4- (trifluoromethyl) phenyl) piperazine-1-) ethyl) -1H-benzimidazol-2-one.
In the early 1990s, neuroscience research confirmed that dysfunction of the serotonin system was closely related to depression. Researchers at Boehringer Ingelheim hoped to develop new drugs with lower side effects than traditional tricyclic antidepressants by optimizing the selectivity of compounds towards 5-HT receptors. Early in vitro experiments showed that BIMT-17 has excitatory activity on 5-HT1A receptors and antagonistic activity on 5-HT2A receptors. This dual mechanism of action can theoretically improve mood by regulating neurotransmitter release.
In 1996, BIMT-17 entered phase I clinical trials to primarily evaluate pharmacokinetic characteristics and safety in healthy subjects. The results showed that the compound reached its peak blood concentration 2 hours after oral administration, with a half-life of approximately 11 hours. It was well tolerated at a dose of 100mg, with only a few subjects experiencing mild drowsiness symptoms.
The R&D team initiated a phase II clinical trial in 1998, which included 237 patients with moderate to severe depression. They were given doses of 50mg and 100mg of BIMT-17 and placebo, respectively, for a treatment period of 8 weeks. However, the experimental results were disappointing: the improvement rates of depression scores in the two dose groups were 32% and 35%, respectively, significantly lower than the control group's 55%, and the incidence of drowsiness in the 100mg dose group increased to 27%, which did not reach the predetermined clinical endpoint.
In 2000, the R&D team adjusted the plan and launched the second phase II trial, attempting to improve efficacy by extending the dosing period to 12 weeks and optimizing the dose gradient, but the results were still not up to standard.
In the 2003 clinical trial data review, researchers discovered an unexpected phenomenon: among the 187 female patients with depression included, 23% of the participants reported a "significant increase in libido" in their self examination reports, while this proportion was only 4% in male participants and was not significantly associated with improvement in depressive symptoms. This discovery caught the attention of sexual medicine experts - at that time, female sexual dysfunction disorder (HSDD) was gradually becoming a medical research hotspot, but there were no targeted approved drugs globally. Boehringer Ingelheim immediately decided to suspend the development of antidepressant indications and turn to exploring its potential applications in the field of sexual health.
Hot Tags: flibanserin drops, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale